XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

Condensed Consolidated Financial Statements Detail (Tables)

9 Months Ended

Sep. 30, 2016

Condensed Consolidated Financial Statements Detail [Abstract]

Accrued and other liabilities consisted of the following (in thousands):

	September 30,		December 31,
	2016		2015
Accrued payroll and other benefits	$	1,682	$	2,156
Deferred rent		782		608
Accrued clinical trial costs		669		406
Accrued incentive compensation		569		2,609
Accrued legal and accounting fees		389		517
Other		723		729
Total	$	4,814	$	7,025

Outstanding securities considered anti-dilutive

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Common stock options and RSUs		558		548		549		481
Warrants for common stock		917		908		915		908
Total		1,475		1,456		1,464		1,389